We are live on
!
Find out more
Neurocrine Biosciences
NBIX
NBIX
223 hedge funds and large institutions have $5.88B invested in Neurocrine Biosciences in 2017 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 98 increasing their positions, 51 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
92% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 51
61% more call options, than puts
Call options by funds: $37.3M | Put options by funds: $23.2M
35% more capital invested
Capital invested by funds: $4.36B → $5.88B (+$1.52B)
22% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 27
1.1% more ownership
Funds ownership: 107.69% → 108.79% (+1.1%)
1% more funds holding
Funds holding: 221 → 223 (+2)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
Holders
223
Holders Change
+2
Holders Change %
+0.9%
% of All Funds
5.56%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.17%
New
33
Increased
98
Reduced
51
Closed
27
Calls
$37.3M
Puts
$23.2M
Net Calls
+$14.1M
Net Calls Change
+$18.9M
Top Buyers
Top Sellers
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
-$53.7M |
| 2 |
SAM
Senzar Asset Management
New York
|
-$34.5M |
| 3 |
HM
HealthCor Management
New York
|
-$24.4M |
| 4 |
Bank of New York Mellon
New York
|
-$18.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$16.4M |
